Clinical Trial

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy,safety of RC48-ADC in Combination with Zimberelimab Injection for the Treatment ,at least first-line platinum-containing standard therapy failed in HER2-expressing subject with Recurrent or Metastatic Cervical Cancer
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-11-23; most recent amendment 2024-02-26.
Status change: Not Yet Recruiting → Recruiting 2024-01-15
Trial Details
NCT Number NCT06155396
Lead Sponsor RemeGen Co., Ltd.
Conditions Cervical Cancer
Enrollment 116 participants
Start Date 2024-01-11
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-02-28